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Abstract
AIM: The aim of the present study was to prepare and characterize the solid dispersion of poorly soluble drugs 
irbesartan with hydrophilic polymer poloxamer 188 by solvent co-evaporation technique.
METHODS: The ratio of irbesartan to poloxamer 188 in solid dispersion system was 1:0.5; 1:1; and 1:3. 
Physicochemical properties characterization was analyzed by X-ray powder diffraction, Fourier-transform infrared 
(FT-IR) spectroscopy, differential thermal analysis, and scanning electron microscopy (SEM). The in vitro dissolution 
rate profile of solid dispersion was performed by Type II United States Pharmacopeia dissolution testing apparatus.
RESULTS: The results of the X-ray powder diffraction pattern showed that the degree of crystallinity of irbesartan 
crystalline phase reduced in a solid dispersion system. FT-IR spectra indicate that there is no chemical interaction 
between irbesartan and poloxamer 188 in a solid dispersion system. SEM microscopy demonstrated a homogenous 
phase of a solid dispersion system with distinct crystal habit. In general, in vitro dissolution rate of all solid dispersions 
was higher than intact irbesartan. The highest percentage of dissolved irbesartan was the solid dispersion of 
irbesartan-poloxamer 188 (1:0.5 w/w).
CONCLUSIONS: The study concludes that the solid dispersion can be applied to improve the dissolution rate of 
irbesartan.
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Introduction
Irbesartan (IBS) is 2-butyl-3-[[2-(1H-tetrazole-
5-yl)(1,1-biphenyl)-4-yl]methyl]-1,3 diazaspiro[4,4]non-
1-en-4-one. IBS, a specific competitive blocker of the 
angiotensin II receptor, is orally used for the treatment 
of hypertension as well as renal disease in hypertensive 
diabetic patients [1]. IBS has a low solubility in water 
(0.00884 mg/mL) with 26% oral bioavailability. It 
belongs to Biopharmaceutics Classification System 
(BCS) Class II drugs. The bioavailability of active 
pharmaceutical ingredients (API) is significantly related 
to the BCS. More than 40% of API in the market are 
categorized as BCS Class II (low solubility and high 
permeability) [2]. The poorly soluble drugs often show 
low gastrointestinal absorption due to low drug solubility 
in the gastrointestinal fluid and dissolution rate of API 
in the gastrointestinal fluids as a rate-limiting step. The 
improvement of dissolution rate of API will significantly 
increase absorption of poorly soluble drug in the 
systemic circulation.
Many strategies had been reported to enhance 
dissolution rates of IBS such as the formation of inclusion 
complexes, nanoparticles, and cocrystal [3], [4], [5]. 
One of the most popular techniques for modifying 
dissolution rates is the formation of a solid dispersion 
system of poorly soluble drugs with hydrophilic 
carriers [6]. According to BCS, the drug is considered 
very soluble when the absorption rate in humans is 
more than 90% of the given dose [7]. Irbesartan shows 
a low oral bioavailability of 26% so a method is needed 
to increase the solubility of the molecule [6].
Solid dispersion system is a dispersion of one 
or more active ingredients in an inert carrier or matrix 
in a solid-state which is prepared by solvent, melted, 
and combination of solvent and melted technique [8]. 
Solid dispersions are intended for solid product groups 
containing at least two different components, generally 
one hydrophilic carrier and one hydrophobic drug. 
Various carriers can be used in solid dispersion systems, 
including polyethylene glycol, polyvinyl pyrrolidone, 
urea, mannitol, and poloxamer [9], [10].
In this study, poloxamer 188 was used as 
a carrier. Poloxamer 188 is a nonionic copolymer 
consisting of ethylene oxide and propylene oxide which 
has been used to increase the solubility, dissolution, and 
bioavailability of drugs with poor solubility in water [11]. 
Poloxamer 188 was empirically chosen to prepare 
solid dispersions due to the low melting point (around 
52-57°C) and the nature of surfactants [12]. In 2009, 
Ghareeb et al. conducted a study on the preparation 
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of a solid dispersion system for binary solutions from 
meloxicam using poloxamer 188 as a carrier [12].
In this study, the physicochemical properties of 
irbesartan in the form of solid dispersion will be studied 
using poloxamer 188 carrier by the solvent method. 
The solid dispersions were characterized using X-ray 
diffraction analysis, Fourier-transform infrared (FT-
IR) spectroscopy, and scanning electron microscopy 
(SEM). The dissolution rate profile of solid dispersions 
of irbesartan was determined using a Type II United 
States Pharmacopeia (USP) apparatus. The formation 
of solid dispersion and the results of analysis of solid 
dispersion systems are expected to improve the 
physicochemical properties of irbesartan.
Materials and Methods
Materials
Irbesartan (Dr. Reddy’s) was kindly obtained as 
a gift from PT. Primatama Tata. Poloxamer 188, ethanol, 
and HCl were purchased from Merck (Germany). 
Paraffin liquid was purchased from PT. Harum Kimia 
(Indonesia).
Methods
Preparation of solid dispersions system and 
physical mixture
Solid dispersions of irbesartan-poloxamer 188 
were prepared by the solvent co-evaporation technique. 
Irbesartan and poloxamer 188 were weighed according 
to the ratio of 1:0.5; 1:1; and 1:3 w/w. Irbesartan and 
poloxamer 188 were dissolved with 96% ethanol until a 
clear solution was formed. The solution was evaporated 
and dried in a vacuum oven at 40°C. The resulting solid 
is crushed, then passed through 60 mesh sieves and 
stored in a desiccator.
Powder X-ray diffraction (PXRD) analysis
The measurement conditions were as follows: 
Cu metal target, Kα filter, voltage 35–40 kV, and current 
40 mA, analysis carried out in the range of 2q at 5–35°. 
Intact irbesartan, poloxamer 188, physical mixture, and 
irbesartan-poloxamer solid dispersion are placed on the 
sample holder (glass) and flattened to prevent particle 
orientation during sample storage.
FT-IR spectrophotometry analysis
Intact irbesartan, poloxamer 188, solid 
dispersion, and physical mixture were dispersed on 
attenuated total reflection which is pressed with high 
pressure. The absorption spectrum was recorded 
with FT-IR spectrophotometry at wave numbers 
4000–400 cm−1.
SEM analysis
Intact irbesartan, poloxamer 188, irbesartan-
poloxamer 188 solid dispersion, and physical mixture 
were placed on an aluminum sample holder. The 
surface morphology of each sample was then observed 
in various magnifications. Voltage was set at 20 kV and 
12 mA current.
Dissolution rate profile
The dissolution rate profile was performed by 
Type II USP apparatus. The equipment was adjusted 
at a speed of 50 rpm and 900 mL dissolution medium 
of 0.1 N hydrochloric acid solution. The temperature 
was maintained at 37 ± 0.5°C. At pre-determined times 
(5; 10; 15; 30; 45; and 60 min), approximately 5 mL of 
aliquot were withdrawn and filtered. The concentration 
of irbesartan in the medium was determined by an 
ultraviolet-visible spectrophotometer at a maximum 
absorption wavelength of 245 nm. The experiment was 
conducted in triplicate.
Results and Discussion
The results of X-ray diffraction analysis can 
be seen in Figure 1. The PXRD pattern showed that 
irbesartan has a high crystalline degree due to the 
presence of a number of distinctive sharp peaks 
at the diffraction angle 2θ = 12.34°; 19.15°; and 
Figure 1: Powder X-ray diffraction pattern for (a) intact irbesartan, 
(b) poloxamer 188, (c) solid dispersion of irbesartan-poloxamer 188 
at ratio 1:0.5, (d) solid dispersion of irbesartan-poloxamer 188 at ratio 
1:1, (e) solid dispersion of irbesartan-poloxamer 188 at ratio 1:3
d
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22.97°, while the poloxamer 188 diffraction pattern 
is semi-crystalline. The diffractogram pattern of solid 
dispersion of irbesartan-poloxamer 188 (1:0.5; 1:1; 
and 1:3) exhibited a decreasing in interference peak 
at diffraction angle 2θ = 12.34° (peak intensity is 
6345,9; 4705,5; 5439,3; 5197,1; 3077,1; and 2915,3). 
The intensity of X-ray diffraction interference peak is 
calculated using WinPLOTR software.
In all solid dispersion samples of irbesartan-
poloxamer 188, there was also a decrease in intensity at 
several peaks but no new peaks were seen. Decreasing 
the intensity of the interference peak shows changes 
in the degree of crystallinity so that it will increase its 
solubility [13]. The results of PXRD analysis showed 
a decrease in the intensity of the interference peak at 
an angle of 2θ = 12.34° from 6345.9 to 2915.3 which 
indicates the formation of a crystal lattice that has a 
level of symmetry.
In the FT-IR spectra (Figure 2), intact 
irbesartan shows that there is a functional group C-H at 
wave number 2953.87 cm−1, functional group C = O at 
wave number 1729.32 cm−1, and functional group C-N 
at wave number 1613.71 cm−1. While the FT-IR spectra 
of poloxamer 188 show a wide peak at wave number 
3503.67 cm−1 which shows the O-H function group, the 
functional group C-H at wave number 2877.71 and the 
functional group C-O at wave number 1095.14 cm−1. The 
results of this FT-IR analysis support the results of the 
previous analysis that the existence of peaks equal to 
the components of intact irbesartan and poloxamer 188 
in all solid dispersion systems and can be proved to be 
the same as the physical mixed spectrum of irbesartan-
poloxamer 188. This shows that there are no chemical 
interaction occurs between the two components of the 
solid dispersion constituent.
Figure 2: Fourier-transform infrared spectrum of (a) intact irbesartan, 
(b) poloxamer 188, (c) solid dispersion of irbesartan-poloxamer 188 
at ratio 1:0.5
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The results of morphological analysis by SEM 
(Figure 3) of irbesartan with a magnification of 2500 × 
look like the surface of a particle that is roughly shaped 
while poloxamer 188 looks like a round particle with 
a smooth surface. The solid dispersion system of 
irbesartan-poloxamer 188 shows that a form of irregular 
particles dispersed molecularly forms an aggregate 
so that it cannot be distinguished from the shape of 
its constituent particles. This indicates that irbesartan 
has been dispersed in carrier polymers to form a solid 
dispersion system. The SEM result shows that the 
occurrence of physical interactions between these two 
substances that will affect the crystal morphology of 
each substance [13], [14].
Figure 3: Scanning electron microscopy microphoto for (a) intact 
irbesartan, (b) poloxamer 188, (c) solid dispersion of irbesartan-
poloxamer 188 at ratio 1:0.5, (d) solid dispersion of irbesartan-
poloxamer 188 at ratio 1:1, (e) solid dispersion of irbesartan-poloxamer 
188 at ratio 1:3
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The dissolution rate profile (Figure 4) was 
carried out in 0.1 N HCl dissolution medium with 
a speed of 50 RPM and tested for 60 min using the 
paddle method. This test is carried out by aliquot 
samples at 5, 10, 15, 30, 45, and 60 min. Irbesartan 
dissolution percentage results in the 60th min for intact 
irbesartan, solid dispersion 1:0.5, 1:1, and 1:3, were 
65.374%, 100%, 94.264%, and 94.538%. Based on the 
results obtained, the highest percentage of dissolved 
substances at minute 60 was shown to be a solid 
dispersion of 1: 0.5, which was completely 100%. The 
increase in the amount of poloxamer 188 resulted in 
a decrease in the amount of irbesartan dissolved, this 
occurred due to poloxamer 188 which was surfactant 
so that irbesartan was trapped by poloxamer 188 
so irbesartan was difficult to release. In addition, the 
increase in the amount of poloxamer 188 causes 
Figure 4: Dissolution profile for irbesartan and solid dispersion system
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the micelles to join to become aggregates of varying 
sizes [15].
According to the pharmacopeia, irbesartan 
must dissolve within 20 min not <80% [16]. While in 
solid dispersion 1: 0.5, irbesartan from solid dispersion 
dissolved approximately 85.240% in 15 min, this 
indicates that the solid dispersion of irbesartan-
poloxamer 188 (1:0.5) has met the requirements as 
stated in the literature.
Conclusions
From the current study, it can be concluded 
that the solid dispersion system of IBS with poloxamer 
188 can modify the physicochemical properties of 
irbesartan such as decreasing the degree of crystallinity 
and surface morphology of substances. The solid 
dispersion system of irbesartan-poloxamer 188 can 
increase dissolution and highest dissolution obtained in 
a ratio of 1:0.5.
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